# Propafenone

## Rhynorm 150mg

##### 

| 標題       | 說明                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|:-----------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 藥品代碼   | ORHY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| 適應症     | Ventricular & supraventricular tachyarrhythmias, Wolff-Parkinson-White syndrome.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| 用法用量   | Adult (70 kg): Initial and maintenance dose: 450-600 mg/day in 2-3 divided doses. May increase to 900 mg/day. Dosage may be adjusted in patients with lower body weight. Children: 10-20mg/kg/day in 3-4 divided doses.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| 肝功能異常 | 需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| 腎功能異常 | 無需調整劑量                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| 禁忌       | Manifest heart failure; cardiogenic shock (except for shock induced by arrhythmia); severe bradycardia within 3 months after MI; pre-existing high degree SA, AV & intraventricular disorders of impulse conduction; sick sinus syndrome; manifest disorders of electrolyte balance; severe obstructive pulmonary disease; marked hypotension, myasthenia gravis.                                                                                                                                                                                                                                                                                                                                                      |
| 副作用     | May induce arrhythmia eg. bradycardia, induction disorder, tachycardia. Rarely ventricular fibrillation. May increase severity of heart failure. Hypotension. GI disturbances. Paresthesia, visual disturbances, dizziness. Rarely fatigue, headache, psychotic disorders. Blood disorders. Rarely, skin allergy, bronchospasm. Cardiovascular: Chest pain (1.8% ), Edema (5% to 13% ), Palpitations (3.4% ) Gastrointestinal: Constipation (8% to 14% ), Nausea (9% to 17% ), Taste sense altered (6% to 22% ), Vomiting (0% to 6% ) Neurologic: Dizziness (21% to 23% ) Psychiatric: Anxiety (10% to 13% ) Respiratory: Dyspnea (13% to 17% ), Upper respiratory infection (8% to 12% ) Other: Fatigue (11% to 13% ) |
| 孕期建議   | No (limited) human data – animal data suggest moderate risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| 哺乳期建議 | No (Limited) Human Data - Probably Compatible 無(很少)資料 - 可使用                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

